Alkermes (ALKS) Stock Gains After Announcing Presentation at Annual ASCP Meeting

NEW YORK (TheStreet) -- Alkermes (ALKS) shares are up 7.41% to $$62.93 in morning trading on Tuesday after the pharmaceutical company announced that it will present the results of the data studies of the central nervous system drug candidates in schizophrenia and depression at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami.

The company will present on ALKS 3831, a possible schizophrenia treatment, as well as a presentation on ALKS 5461, a potential major depressive disorder treatment. The meeting runs from June 22 to June 25.

The presentation on ALKS 3831 will be one of the highlights of the event and the company will hold a conference call next Tuesday before the oral presentation to discuss the treatment.

TheStreet Ratings team rates ALKERMES PLC as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:

"We rate ALKERMES PLC (ALKS) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

ALKS Chart ALKS data by YCharts

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%